We investigated the possibility of labeling two biologically active peptides, epidermal growth factor (EGF) and neurotensin (NT), with europium (Eu)-diethylenetriaminepentaacetic acid. More specifically, we tested them as probes in studying receptor binding using time-resolved fluorescence of Eu Da can be conveniently accomplished. Importantly, the Eu-labeled products are stable for approximately 2 years and are completely safe for laboratory use compared to the biohazardous radioligands. Thus, Eu-labeled peptides present an attractive alternative for commonly used radiolabeled ligands in biological studies in general and in receptor assays in particular.
Growth factor and peptide hormone receptors appear on the cell's outer surface in relatively low numbers, usually 10 3 -10 6 sites per cell, with binding affinities in the picomolar to nanomolar range. To determine the bioactivity of these receptors, hormone binding or metabolic responses have been widely used in pharmacological, biochemical, and clinical diagnosis. Moreover, the disappearance, overexpression, or malfunctions of these receptors serve as clinical diagnostic tools (1) . For instance, overexpression of the epidermal growth factor (EGF) 2 receptor is associated with the prognosis of certain types of breast cancer (2) , and the overexpression of neurotensin (NT) receptors has been linked to ductal pancreatic adenocarcinoma and colorectal carcinoma (3, 4) .
Receptor binding assays using EGF or NT are commonly performed with labeled 125 I or 3 H peptides (4, 5) and are considered highly sensitive, permitting the detection of the respective receptors in the femtomolar to picomolar range. However, radioactively labeled ligands have drawbacks including their short shelf life, their high costs, the logistics involved in their handling, and often the need to prepare them shortly before use, as well as the safety hazards involved (6) .
To overcome some of these problems, alternative, nonradioactive methods using chemiluminescent or fluorescent markers or enzymes have been employed to label antibodies, hormones, and drugs for immunoassay use. Fluorescent tags using lanthanide chelate (e.g., Eu 3ϩ , Sm 3ϩ , and Tb 3ϩ ) labels offer sensitivity comparable to that of radiolabeled ligands. Such lanthanide chelates are exceptionally well-adapted reporter groups for analytical procedures in biomedicine due to their unique fluorescent properties. Among these one can list high quantum yield, extremely large Stoke's shift, narrow emission peaks, and optimal emission and excitation wavelengths (Eu 3ϩ 613 nm) for analysis in biological material. The long fluorescent decay time (10 -1000 s) permits time-resolved analysis with high signal-to-noise ratios and high sensitivity. Application of this technique has been adapted to standard microplate readers (7) (8) (9) . However, the use of lanthanide chelates is not widespread. Thus, drug labeling (e.g., benzodiazepine) (10) and cytokine labeling such as interleukin-8 (11) with Eu 3ϩ chelate, and their use in determining of drug-receptor interactions, have seldom been reported.
In this paper we describe EGF and NT labeling with Eu 3ϩ chelates and the receptor binding and bioactivity (Ca 2ϩ influx and cell proliferation) of the labeled products. Our results indicate that this nonisotopic labeling method is an advantageous alternative for radioactive labeling of these ligands. The sensitivities obtained are similar to those achieved with radioreceptor assays. Moreover, Eu-labeled EGF and NT are stable for over a year with no loss of activity and are safe and inexpensive.
EXPERIMENTAL PROCEDURES

Materials
Enhancement solution for measuring Eu-fluorescence was purchased from Wallac (Turku, Finland). Thiazolyl blue (MTT), human recombinant-EGF, and diethylene triaminepentaacetic acid (DTPA) dianhydride were purchased from Sigma Chemical Co. (St. Louis, MO). NT was obtained from Neosystem (Strasbourg, France). Cell culture media were prepared by the Biological Services Department of the Weizmann Institute and Gibco, France. Europium chloride (EuCl 3 ) was purchased from Aldrich (St. Louis, MO). Fura-2/AM was purchased from Molecular Probes (Interbiotech, France). The labeling reagent N-1(p-isothiocyanatophenyl)diethylene tri-N 1 , N 2 , N 3 ,-tetraacetate chelated with europium (activated Eu-chelate) was kindly provided by Dr. I. Hemmila, Wallac.
Synthesis of Eu-EGF
To a test tube were added 100 l Na-phosphate (0.1 M, pH 8.5), 50 l activated Eu-chelate (150 nmol), and 10 l EGF (100 g, 17 nmol) and the mixture was incubated overnight at 4°C with constant stirring. To terminate the reaction, 1 l Tris-Cl (1 M, pH 8.2) was added and the mixture was stirred for 5 min. Next the reaction mixture was loaded and chromatographed on a Bio-Gel P-2 cartridge (11 ml, Bio-Rad) preequilibrated with 0.1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), and 40 fractions (320 l) were collected and Eu-fluorescence was determined using a time-resolved fluorimeter (LKB-Wallac, Arcus 1230). Eu-fluorescence eluted in three peaks (fractions 10 -15 (11.6%), 19 -25 (24.9%), and 25-40 (63.5%)) with a total yield of 70%. Analysis of the fractions by ligand-receptor binding showed Eu-EGF to be present in the first peak only. The two fractions with the highest fluorescence (12 and 13) were used. Repeated chromatography of these fractions under the same conditions recovered the product Eu-EGF with a yield of 70%. Characterization of the Eu-EGF by mass spectrometry using matrix-assisted laser desorption-ionization/time-of-flight Reflex (Bruker Daltonik, Germany) revealed a 1:1 molar ratio of Eu and EGF (experimental mass: Eu-EGF ϭ 6824.3; EGF ϭ 6342.4). The specific activity of the Eu-EGF was estimated to be 8 ϫ 10 6 fluorescence units (FU)/pmol based on the biological activity of the fraction.
Synthesis of the DTPA-NT Analogue
The DTPA-NT analogue was obtained by reacting DTPA dianhydride with the -amino group of Lys 6 of NT (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-TyrIle-Leu) using a procedure similar to that described by Janevik-Ivanovska et al. (12) . Briefly, 1.8 mol of NT (220 l) in Hepes buffer (0.6 M, pH 8.2, filtered through Chelex 100 (Bio-Rad)) was added with stirring to 14.5 mol of DTPA dianhydride in DMSO (220 l); the pH was kept at 8.2 until the reaction was completed. After the solvents were evaporated, the crude product was dissolved in water and trifluoroacetic acid (TFA) was added to reach pH 2. Finally the solution was filtered through Chelex 100 (Bio-Rad). The resulting peptide was purified by HPLC C-18 reverse phase chromatography (Nucleosil, Shandon, France) using a linear 15-min gradient (A: H 2 O/TFA 0.05%, B: acetonitrile) from 0 to 26% B followed by a linear 20-min gradient from 26 to 30%. The yield of DTPA-NT was 43% with a purity of Ն95% as verified by C18 reverse phase chromatography under isocratic conditions (acetonitrile 30%, H 2 O TFA 0.05%). The DTPA-NT analogue was further characterized by mass spectrometry using a Nermag R10-10 mass spectrometer with an electrospray ion source equipped with an iron guide (Analytica of Branford), experimental mass: 2048.16, calculated mass: 2048.32.
Preparation of Eu-NT
DTPA-NT (100 g, 50 nmol) was dissolved in 10 l of H 2 O, and added to 490 l of citrate buffer (10 mM, pH 5.0) containing freshly dissolved EuCl 3 (50 nmol). The reaction mixture was incubated for 1 h at room temperature and neutralized with 5 l 1 N NaOH. Next, the mixture was loaded on a Sep-Pak C-18 cartridge and washed with 10 ml of H 2 O to elute the free Eu. The column was washed with 17.5 ml of 50% MeOH and the Eu-NT was quantitatively eluted as a single peak (fractions 40 -45). An additional wash with 100% methanol did not elute any Eu-containing material. The specific activity of this peak was estimated to be 2.5 ϫ 10 6 FU/pmol or ϳ1 Eu 3ϩ ion per DTPA-NT molecule based on the biological activity of the fraction. (5) were cultured as monolayers in Dulbecco's modified Eagle's medium (DMEM) with fetal bovine serum (FBS) (10%), glutamine (2 mM), penicillin (0.06 mg/ml), and streptomycin (0.1 mg/ml).
Cell Lines
A431 human epithelial carcinoid cells. A431 cells expressing EGF receptors
HT29 human colon carcinoma. HT29 cells expressing high-affinity NT1 receptors (13) were cultured as monolayers in DMEM:F12 (1:1), buffered with Hepes (25 mM, pH 7.4), FBS (10%), glutamine (2 mM), penicillin (0.06 mg/ml), and streptomycin (0.1 mg/ml).
Murine D1 hematopoietic cells. D1 cells expressing EGF receptor (ErbB1, kindly donated by Y. Yarden, Weizmann Institute, Israel) were cultured in suspension as described (14) .
Chinese hamster ovary (CHO)-NT1 cells. CHO cells transfected with NT1 receptor were cultured as described earlier (15) .
Ligand Binding Assays
Eu-EGF binding. A431 cells (4 ϫ 10 5 cells/well) cultured in 48-well plates for 48 h were washed once with ice-cold binding medium (DMEM ϩ 0.1% BSA and Hepes 25 mM, pH 7.4). The cells were further incubated for 2 h at 4°C in the same medium with increasing concentrations of Eu-EGF (as indicated in the individual experiments). Binding was terminated by four successive washes with ice-cold binding medium. Enhancement solution (300 l/well) was then added to the cells and the samples (200 l) were taken for timeresolved fluorescence determination using an Arcus fluorometer.
Eu-NT binding. HT29 cells (4 ϫ 10 5 cells/well) cultured in 48-well plates for 48 h were washed once with binding medium (DMEM: F12 ϩ 0.1% BSA and Hepes 25 mM, pH 7.4) and further incubated for 30 min at 37°C in the same medium with increasing concentrations of Eu-NT. All other details were as previously described for binding Eu-EGF to A431 cells.
Calculations. Nonspecific binding was determined for both Eu-EGF and Eu-NT studies in the presence of 1-3 M unlabeled ligand. The obtained values were subtracted from the total binding values to estimate the net bound ligand. Molar quantities were calculated from the respective specific activities of the relevant Eu-labeled ligands. Experiments in triplicate were repeated at least three times and representative experiments are shown. Dissociation constants were calculated by Scatchard analysis.
I-NT Binding
125 I-NT binding was performed on CHO-NT1 cell membranes as previously described (15) . Cell membranes (15-20 mg/ml) were kept frozen at Ϫ80°C until used. Binding of 125 I-NT was performed with a 10-g membrane protein/tube in 50 mM Tris-Cl buffer (pH 7.4) containing 5 mM MgCl 2 , 0.2% BSA, and 0.8 mM 1,10-o-phenanthroline, in the presence of 0.5 nM 125 ITyr 3 -NT (2000 Ci/mmol) and increasing concentrations of NT or Eu-NT, for 30 min at room temperature. Bound 125 I-NT was determined after filtration (Whatman GFC filters) and washing with 50 mM Tris-Cl containing 0.2% BSA. Nonspecific binding was determined in the presence of 1 M unlabeled NT. Specific binding was calculated by subtracting nonspecific values. One hundred percent binding was obtained with a tracer alone. The data of the competition, using increasing concentrations of NT or Eu-NT (0.01-500 nM), were analyzed using the EBDA-ligand program to estimate the K 0.5 for both NT and Eu-NT.
Cell Proliferation Assay for EGF
Murine D1 hematopoietic cells were washed once in RPMI 1640 medium and resuspended to 5 ϫ 10 5 cells/ ml. Portions (100 l) of the cell suspension were incubated for 24 h in 96-well plates with the indicated concentrations of Eu-EGF or EGF. Cell survival was determined by MTT assay (14) . In short, MTT (0.1 mg/ml) was added to the analyzed cells, which were incubated for 2 h at 37°C. The cells were then lysed in acidic isopropyl alcohol and optical density was determined at 570 nm in a microplate reader (Dynex MRX II).
Determination of Intracellular Free Ca 2ϩ
Concentration
The intracellular Ca 2ϩ concentration was measured in response to activation of NT1 receptors using a dynamic imaging microscopy system QuantiCell 700 (Visitech Int. Ltd., UK) with 30 -40 CHO-NT1 cells per field as described earlier (16) (Fig. 1) . Binding of Eu-EGF in the nanomolar range was dosedependent, with nonspecific binding Յ10% up to ligand concentrations of 5 nM, reaching a maximum of Ͻ25% of the total binding at 20 nM. The calculated binding constant (K d ) was (nM) ϭ 3.6 Ϯ 1.2 SEM (n ϭ 4) and maximal binding B MAX ϭ (sites/cell) 1.5 Ϯ 0.2 ϫ 10 6 SEM (n ϭ 4).
RESULTS
Studies with Eu-EGF
A. Eu-EGF binding to cultured A431 cells. Specific Eu-EGF binding to A431 cells was determined
B. Induction of proliferation response in D1 cells by Eu-EGF.
In order to estimate the biological activity of Eu-EGF, its ability to stimulate proliferation of D1 cells was compared to native EGF. To this end, cells were incubated with increasing concentrations of Eu-EGF. It was found that D1 cell proliferation was stimulated in a dose-dependent manner, with a maximal effect at 1 nM (Fig. 2) , a response similar to that obtained with native EGF, suggesting that the bioactivity of the Eu-EGF was preserved during the chemical manipulations involved in its preparation.
Studies with Eu-NT
A. Binding of Eu-NT to HT29 cells. Binding of Eu-NT to HT29 cells showed a concentration-dependent increase in the nanomolar range, reaching saturation at approximately 25 nM (Fig. 3) . 
B. Ca 2ϩ mobilization in CHO-NT1 cells in response to Eu-NT.
The bioactivities of Eu-NT and NT were determined by their ability to induce Ca 2ϩ transients in CHO-NT1 cells (Fig. 4) . The maximal cytosolic Ca 2ϩ concentration induced was similar for both peptides (about 650 nM); however, the potency of Eu-NT (K 0.5 ϭ 1 nM) was about 50 times lower than that of the native NT (K 0.5 ϭ 0.02 nM).
DISCUSSION
In this study we synthesized two Eu-labeled peptides and demonstrated their ability to serve as labeled ligands in studying ligand-receptor binding and consequent physiological responses. In the case of EGF the results obtained were similar to published reports obtained with 125 I-EGF (5). In the case of Eu-NT the biological activity was markedly affected for reasons discussed below.
Over the past 2 decades, Eu 3ϩ labeling was used to replace radioisotopic label of antibodies in immunoassays (9), drugs (10), chemokines (11), or cell cytotoxicity assays (17) . The use of time-resolved fluorescence in place of radioactivity has many advantages aside from safety concerns. The low basal Eu concentration in biological samples, combined with the delayed fluorescence measurement, provides a highly sensitive detection of the Eu ions (up to 8 ϫ 10 Ϫ18 mol per sample) (8). A431 cells were reported to express two EGF receptor populations, a small fraction (0.1-0.2%) with high affinity (K d ϭ 70 pM) , and a majority with low affinity (K d ϭ 5 nM) (5). The results obtained in the present study with Eu-EGF yielded a binding constant of K d ϭ 3.6 nM, likely to represent the larger low-affinity subpopulation of EGF receptors (Fig. 1) . The EGF receptor density measured on A431 cells, using Eu-EGF (1.5 ϫ 10 6 sites per cell), is also in agreement with published data obtained with 125 I-EGF for the low-affinity receptor population (1-3 ϫ 10 6 sites per cell) (5). Considering the specific activities of the two labeled EGF ligands, their nearly identical values of K d , and nonspecific binding on A431 cells one can predict that the binding assays have essentially identical sensitivities. Consequently, high-affinity binding sites of the kind described by Kawamoto et al. (5) could be detected with Eu-EGF in our A431 cell colony (if present). As judged by the stimulatory effect on the proliferation of murine D1 hematopoietic cells (Fig. 2) , the bioactivity of EGF was also unaffected by conjugation with the Eu-DTPA chelate. The human recombinant EGF used here has two candidate -amino groups on Lys residues in positions 28 and 48, as well as an N-terminal amino group that can conjugate with Eu-chelate. These residues appear to reside in regions that apparently play no major role in EGF bioactivity. The calculated specific activity suggests that all three possible positions on the labeled EGF are modified, enabling receptorbinding studies in the picomolar to nanomolar concentration range.
In contrast to EGF, a 54-amino-acid polypeptide, the potency of the smaller NT, a 13-amino-acid peptide, was markedly affected by conjugation of the Eu-DTPA chelate to the -amino group of Lys 6 . The binding affinity (K d ) of the Eu-NT to HT29 cells was determined to be 7.4 nM (Fig. 3) , approximately 10-fold lower than reported earlier for 125 I-NT in the same cell line (13) . In other experiments, carried out with the same cells (data not shown), we observed that the K d values for indium-DTPA-NT were similar to those obtained with Eu-NT, suggesting that the lower receptor binding activity of Eu-NT can be related to the conjugated DTPA moiety rather than to the character of the chelated atom. In agreement with the impaired binding capacity, intracellular Ca 2ϩ mobilization by Eu-NT was even less efficient compared with native NT. The observation that Ca 2ϩ mobilization can be obtained at low NT concentrations may be related to the fact that only a small fraction of the high-affinity NT receptors is required to fully activate Ca 2ϩ mobilization as previously reported (18) . On the other hand, it is possible that the same efficacy of NT and Eu-NT on Ca 2ϩ mobilization relates to the amplification process taking place in the endoplasmic reticulum (18) . Decline of the ligand-receptor affinity due to peptide modification has been reported in other cases where DTPA labeling of bioactive peptides has been described (19) . [ 111 In]-DTPA-MSH(bis-DHP), an ␣-melanocyte stimulating hormone (␣-MSH) homologue, was found to have a 10-fold higher K d than ␣-MSH but was found to be a better imaging agent then other analogues with higher receptor affinity. Similarly, Eu-NT remains a useful ligand for such assays: (i) as a tracer in competition receptor binding studies of NT receptor agonists and antagonists, (ii) in the detection and determination of NT in biological fluids using immunoassays with anti NT antibodies, and (iii) for detection of NT receptors in cell and tumor preparations as is routinely performed with [
111 In]-DTPA-NT having the same properties. It is expected that modification with Eu-DTPA will induce various effects on the bioactivity of ligands and peptides characteristic to each ligand. Such effects will be difficult to predict; most probably more dominant changes will be seen among small peptides than in macromolecular ligands. As with isotopic labeling, the acceptable range of bioactive change, termed the isotope effect, is determined by the analytical purpose intended. Eu-modified ligands remain stable for up to 2 years when kept under appropriate storage conditions, a great advantage when compared to short-lived radiolabeled peptides, which usually remain active for only a few weeks. The relatively long shelf life of the Eulabeled ligands allows higher reproducibility of results, since the same stock of labeled ligands can be used for longer periods. Eu labeling can also reduce the costs involved in labeling and handling, often involved in using isotopically labeled materials. The synthesis of the Eu-labeled peptides could be accomplished in a single-step process by conjugation of the Eu-DTPA chelate to the peptide as described in the preparation of EGF or in a two-step process as described for the preparation of Eu-NT, where the synthesis of DTPA-NT was followed by the chelation of Eu into the complex. Attempts to synthesize Eu-NT by the single-step process were unsuccessful.
In conclusion, this work represents a novel alternative for nonradioactive labeling of small peptides such as EGF and NT, which can replace the commonly used radioactive labeling. Eu labeling of ligands presents several valuable advantages over radiolabeling. The introduction of Eu-labeled peptides for binding studies in routine diagnostic tests may also enable their use in automated tasks, which for purely practical reasons was not possible with radioactive homologues. It can be expected that other peptide hormones will be amenable to Eu-labeling, enabling a reduction in the use of radioactivity in routine laboratory work and the introduction of more advanced medical diagnostics.
